Philippe Gautret

Dr. Philippe Gautret


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
SASophie Amrane
Sophie Amrane
HTHervé Tissot-Dupont
Hervé Tissot-Dupont
BDBarbara Doudier
Barbara Doudier
CECarole Eldin
Carole Eldin
MHMarie Hocquart
Marie Hocquart
PGPhilippe Gautret
Philippe Gautret

28 August 2018 in Current Infectious Disease Reports
Verified
Journal Article
Closed access
PDF file
VHVan Thuan Hoang
Van Thuan Hoang
PGPhilippe Gautret
Philippe Gautret

17 November 2010 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
VFVanessa Field
Vanessa Field
PGPhilippe Gautret
Philippe Gautret
PSPatricia Schlagenhauf
Patricia Schlagenhauf
GBGerd-Dieter Burchard
Gerd-Dieter Burchard
ECEric Caumes
Eric Caumes
TNthe EuroTravNet network
the EuroTravNet network
Background: Europeans represent the majority of international travellers and clinicians encountering returned patients have an essential role in recognizing, and communicating travel-associated public health risks. Methods: To investigate the morbidity of travel associated infectious diseases in European travellers, we analysed diagnoses with demographic, clinical and travel-related predictors of disease, in 6957 ill returned travellers who presented in 2008 to EuroTravNet centres with a presumed travel associated condition. Results: Gastro-intestinal (GI) diseases accounted for 33% of illnesses, followed by febrile systemic illnesses (20%), dermatological conditions (12%) and respiratory illnesses (8%). There were 3 deaths recorded; a sepsis caused by Escherichia coli pyelonephritis, a dengue shock syndrome and a Plasmodium falciparum malaria. GI conditions included bacterial acute diarrhea (6.9%), as well as giardiasis and amebasis (2.3%). Among febrile systemic illnesses with identified pathogens, malaria (5.4%) accounted for most cases followed by dengue (1.9%) and others including chikungunya, rickettsial diseases, leptospirosis, brucellosis, Epstein Barr virus infections, tick-borne encephalitis (TBE) and viral hepatitis. Dermatological conditions were dominated by bacterial infections, arthropod bites, cutaneous larva migrans and animal bites requiring rabies post-exposure prophylaxis and also leishmaniasis, myasis, tungiasis and one case of leprosy. Respiratory illness included 112 cases of tuberculosis including cases of multi-drug resistant or extensively drug resistant tuberculosis, 104 cases of influenza like illness, and 5 cases of Legionnaires disease. Sexually transmitted infections (STI) accounted for 0.6% of total diagnoses and included HIV infection and syphilis. A total of 165 cases of potentially vaccine preventable diseases were reported. Purpose of travel and destination specific risk factors was identified for several diagnoses such as Chagas disease in immigrant travellers from South America and P. falciparum malaria in immigrants from sub-Saharan Africa. Travel within Europe was also associated with health risks with distinctive profiles for Eastern and Western Europe. Conclusions: In 2008, a broad spectrum of travel associated diseases were diagnosed at EuroTravNet core sites. Diagnoses varied according to regions visited by ill travellers. The spectrum of travel associated morbidity also shows that there is a need to dispel the misconception that travel, close to home, in Europe, is without significant health risk.

28 October 2020 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
TDThi Loi Dao
Thi Loi Dao
VHVan Thuan Hoang
Van Thuan Hoang
PGPhilippe Gautret
Philippe Gautret
Many studies have shown that re-positive tests for SARS-CoV-2 by RT-PCR in recovered COVID-19 patients are very common. We aim to conduct this review to summarize the clinical and epidemiological characteristics of these patients and discuss the potential explanations for recurrences, the contagiousness of re-detectable positive SARS-CoV-2 virus, and the management of COVID-19 patients after discharge from hospital. The proportion of re-positive tests in discharged COVID-19 patients varied from 2.4 to 69.2% and persisted from 1 to 38 days after discharge, depending on population size, age of patients, and type of specimens. Currently, several causes of re-positive tests for SARS-CoV-2 in recovered COVID-19 patients are suggested, including false-negative, false-positive RT-PCR tests; reactivation; and re-infection with SARS-CoV-2, but the mechanism leading to these re-positive cases is still unclear. The prevention of re-positive testing in discharged patients is a fundamental measure to control the spread of the pandemic. In order to reduce the percentage of false-negative tests prior to discharge, we recommend performing more than two tests, according to the standard sampling and microbiological assay protocol. In addition, specimens should be collected from multiple body parts if possible, to identify SARS-CoV-2 viral RNA before discharge. Further studies should be conducted to develop novel assays that target a crucial region of the RNA genome in order to improve its sensitivity and specificity.

1 November 2014 in Emerging Infectious Diseases
Verified
Journal Article
Open access
SBSamir Benkouiten
Samir Benkouiten
Remi CharrelRemi Charrel
Remi Charrel
KBKhadidja Belhouchat
Khadidja Belhouchat
TDTassadit Drali
Tassadit Drali
ANAntoine Nougairede
Antoine Nougairede
PGPhilippe Gautret
Philippe Gautret
Pilgrims returning from the Hajj might contribute to international spreading of respiratory pathogens. Nasal and throat swab specimens were obtained from 129 pilgrims in 2013 before they departed from France and before they left Saudi Arabia, and tested by PCR for respiratory viruses and bacteria. Overall, 21.5% and 38.8% of pre-Hajj and post-Hajj specimens, respectively, were positive for ≥1 virus (p = 0.003). One third (29.8%) of the participants acquired ≥1 virus, particularly rhinovirus (14.0%), coronavirus E229 (12.4%), and influenza A(H3N2) virus (6.2%) while in Saudi Arabia. None of the participants were positive for the Middle East respiratory syndrome coronavirus. In addition, 50.0% and 62.0% of pre-Hajj and post-Hajj specimens, respectively, were positive for Streptococcus pneumoniae (p = 0.053). One third (36.3%) of the participants had acquired S. pneumoniae during their stay. Our results confirm high acquisition rates of rhinovirus and S. pneumoniae in pilgrims and highlight the acquisition of coronavirus E229.

1 June 2015 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
ZMZ.A. Memish
Z.A. Memish
Abdullah M. AsiriAbdullah M. Asiri
Abdullah M. Asiri
ATA. Turkestani
A. Turkestani
Saber YezliSaber Yezli
Saber Yezli
MMM. al Masri
M. al Masri
PGPhilippe Gautret
Philippe Gautret